1. GPCR/G Protein
    Immunology/Inflammation
  2. CXCR
  3. Ladarixin

Ladarixin (Synonyms: DF 2156A free base)

Cat. No.: HY-19519 Purity: 99.71%
Handling Instructions

Ladarixin (DF 2156A) is an orally available, allosteric non-competitive and dual CXCR1 and CXCR2 antagonist. Ladarixin (DF 2156A) is used in the study for COPD and asthma study.

For research use only. We do not sell to patients.

Ladarixin Chemical Structure

Ladarixin Chemical Structure

CAS No. : 849776-05-2

Size Price Stock Quantity
Solution
10 mM * 1 mL in DMSO USD 220 In-stock
Estimated Time of Arrival: December 31
Solid + Solvent
10 mM * 1 mL
ready for reconstitution
USD 220 In-stock
Estimated Time of Arrival: December 31
Solid
5 mg USD 200 In-stock
Estimated Time of Arrival: December 31
10 mg USD 350 In-stock
Estimated Time of Arrival: December 31
25 mg USD 700 In-stock
Estimated Time of Arrival: December 31
50 mg   Get quote  
100 mg   Get quote  

* Please select Quantity before adding items.

Customer Review

Based on 1 publication(s) in Google Scholar

Top Publications Citing Use of Products

View All CXCR Isoform Specific Products:

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Ladarixin (DF 2156A) is an orally available, allosteric non-competitive and dual CXCR1 and CXCR2 antagonist. Ladarixin (DF 2156A) is used in the study for COPD and asthma study[1].

In Vitro

Ladarixin inhibits human polymorphonuclear leukocyte (PMN) migration to CXCL8 (IC50 at 0.7 nM)[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Ladarixin (10 mg/kg, orally, once a day) reduces allergic airway inflammation in a model of single OVA exposure. Ladarixin reduces allergic airway inflammation, remodeling, and bronchial hyperreactivity in a model of chronic OVA exposure[1].
Ladarixin(10 mg/kg, orally, once a day for 8 days) reduces pulmonary inflammation and fibrosis induced by bleomycin in Mice[1].
Ladarixin (10 mg/kg, orally, once a day for 3 days) protects mice from cigarette smoke-induced exacerbation of influenza-A infection[1].
Ladarixin was also effective in decreasing CXCL8-induced polymorphonuclear leukocyte infiltration in several animal models without a significant dose-related reduction in systemic neutrophil counts[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Mice (cigarette smoke–induced exacerbation of Influenza-A infection model)[1].
Dosage: 10 mg/kg.
Administration: Orally once a day.
Result: Ladarixin (10 mg/kg) orally given at days 2, 3 and 4 post-infection significantly attenuated the exacerbation in lethality and respiratory changes noted in CSFlu group.
Molecular Weight

375.34

Formula

C₁₁H₁₂F₃NO₆S₂

CAS No.
SMILES

O=S(C(F)(F)F)(OC1=CC=C([[email protected]@H](C)C(NS(=O)(C)=O)=O)C=C1)=O

Shipping

Room temperature in continental US; may vary elsewhere.

Storage
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
Solvent & Solubility
In Vitro: 

DMSO : 100 mg/mL (266.43 mM; Need ultrasonic)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 2.6643 mL 13.3213 mL 26.6425 mL
5 mM 0.5329 mL 2.6643 mL 5.3285 mL
10 mM 0.2664 mL 1.3321 mL 2.6643 mL
*Please refer to the solubility information to select the appropriate solvent.
In Vivo:
  • 1.

    Add each solvent one by one:  50% PEG300    50% saline

    Solubility: 10 mg/mL (26.64 mM); Suspended solution; Need ultrasonic

  • 2.

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 2.5 mg/mL (6.66 mM); Clear solution

  • 3.

    Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in saline)

    Solubility: ≥ 2.5 mg/mL (6.66 mM); Clear solution

  • 4.

    Add each solvent one by one:  10% DMSO    90% corn oil

    Solubility: ≥ 2.5 mg/mL (6.66 mM); Clear solution

*All of the co-solvents are provided by MCE.
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.
  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2

Keywords:

LadarixinDF 2156ACXCRCXC chemokine receptorsC-X-C motif chemokine receptorsneutrophils (PMNs)asthmafibrosischronicobstructivepulmonarydiseaseinfluenza AH1N1COPDInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

 

Salutation

Applicant Name *

 

Email address *

Phone number *

 

Organization name *

Department *

 

Requested quantity *

Country or Region *

     

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Ladarixin
Cat. No.:
HY-19519
Quantity:
MCE Japan Authorized Agent: